CellsBin, a biotechnology company pioneering Rare-Cell Biology, has closed its Series A financing round led by 108 BioCapital. The company is building a new observational layer for precision medicine through its Rare-Cell Intelligence Platform. The capital will support commercial acceleration, strategic partnerships, product development, and the growth of clinical and technical capabilities.
Platform and Technology
The Rare-Cell Intelligence Platform combines advanced microfluidics, patented multimodal imaging, single-cell analysis, and artificial intelligence to reveal biological signals that conventional methods often miss. It provides ultrasensitive rare-cell detection, high-dimensional cellular profiling, longitudinal biological monitoring, proprietary datasets, and AI-driven analysis. These integrated capabilities are designed to help researchers and clinicians understand therapeutic cell behavior, disease evolution, and patient-specific responses to cell therapy.
Applications in Cell Therapy and Oncology
CellsBin is initially focusing its applications on cell and gene therapy monitoring and hematologic cancers. The company aims to establish Rare-Cell Biology as a foundational discipline across research, drug development, and clinical medicine. By making rare cells visible, measurable, and actionable, the platform can help clinicians and scientists make earlier and more precise decisions.
Investor Perspectives
Sasha Bakhru, Managing Partner of 108 BioCapital, said the company is creating a differentiated platform at the intersection of single-cell biology, artificial intelligence, and translational medicine. He explained that detecting and characterizing extremely rare cells could unlock important insights into therapeutic response, disease progression, and patient outcomes. Bakhru also noted the CellsBin team's scientific rigor, platform vision, and commitment to translating complex biology into actionable intelligence.
Use of Financing Proceeds
The Series A proceeds will be used to accelerate commercial adoption and to expand strategic and channel partnerships. CellsBin also plans to advance its research and product development roadmap, strengthen its clinical evidence base, and grow its commercial, scientific, and technical teams. These investments are intended to support the company's next phase of growth and deepen its market presence.
Leadership Vision
Shahryar Oveissi, General Partner of 108 BioCapital, said the firm is excited to support CellsBin as it expands its network of strategic, clinical, and commercial relationships. He added that leading healthcare institutions are already showing strong interest in the company's technology and its potential to create meaningful clinical impact. Oveissi believes the 108 BioCapital ecosystem can help accelerate CellsBin's next phase of growth.
Company Mission and Vision
Ali Kabiri, PhD, Co-founder and Chief Executive Officer of CellsBin, described the financing as an important milestone in the company's mission to make rare cells visible, measurable, and clinically actionable. He said 108 BioCapital shares the conviction that rare cells contain critical biological information that can enable earlier, more precise, and more confident decisions. Kabiri added that the partnership will help advance the Rare-Cell Intelligence Platform, deepen market and channel reach, and build capabilities required to establish Rare-Cell Biology as a new foundation for understanding disease and therapeutic response.
Strategic Outlook
With growing interest from healthcare institutions and a clear focus on cell and gene therapy monitoring, CellsBin is positioned to turn rare-cell insights into practical clinical tools. The company's integrated approach may help address gaps in how therapeutic responses are monitored and how complex diseases are understood. As the platform matures, CellsBin could play a central role in shaping a new standard for precision medicine.
The closing of the Series A financing marks a significant step for CellsBin as it builds a new observational layer for precision medicine. The support from 108 BioCapital will help the company accelerate commercial adoption, expand partnerships, and strengthen its clinical evidence base. With its Rare-Cell Intelligence Platform, CellsBin aims to make rare cells a practical source of biological insight for researchers and clinicians.